The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

As a leader in its category, Sinotau is probably hoping to follow in the footsteps of Hengrui Pharmaceuticals (1276.HK; ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

The rollout marks a new chapter for men with prostate cancer, the most common cancer in Canadian men aside from skin cancer, ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...

Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.